Theriva Biologics Inc.

09/23/2024 | Press release | Distributed by Public on 09/23/2024 06:18

Theriva™ Biologics logra el objetivo de inscripción de pacientes en VIRAGE, el ensayo de Fase 2b de VCN 01 con gemcitabina/nab paclitaxel para el tratamiento del cáncer de[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.